Stockscreener 앱 받기
247.07
3.85%
-9.90
시간 외 거래:
247.07
전일 마감가:
$256.97
열려 있는:
$256.47
하루 거래량:
662.25K
Relative Volume:
2.33
시가총액:
$26.47B
수익:
$3.32B
순이익/손실:
$-860.46M
주가수익비율:
-29.70
EPS:
-8.32
순현금흐름:
$-1.04B
1주 성능:
-9.10%
1개월 성능:
+10.55%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$245.52
$256.52
1주일 범위
$240.00
$264.87
52주 변동 폭
$172.67
$287.88
Beone Medicines Ltd Adr Stock (ONC) Company Profile
명칭
Beone Medicines Ltd Adr
전화
13459494123
주소
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
247.07 | 26.47B | 3.32B | -860.46M | -1.04B | -8.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.29 | 125.39B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.51 | 77.35B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.21 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
244.52 | 31.65B | 2.25B | -278.16M | -42.59M | -2.17 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-12-03 | 재개 | Morgan Stanley | Overweight |
| 2024-09-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-06 | 재개 | JP Morgan | Overweight |
| 2023-09-12 | 개시 | Macquarie | Outperform |
| 2023-08-17 | 개시 | Jefferies | Buy |
| 2023-07-17 | 개시 | Citigroup | Buy |
| 2023-06-30 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 개시 | Daiwa Securities | Buy |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-10-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 재개 | JP Morgan | Overweight |
| 2022-03-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 개시 | Deutsche Bank | Buy |
| 2021-10-12 | 개시 | Bernstein | Outperform |
| 2021-10-06 | 업그레이드 | CLSA | Underperform → Buy |
| 2021-03-08 | 개시 | China Renaissance | Buy |
| 2021-03-01 | 다운그레이드 | CLSA | Outperform → Underperform |
| 2020-11-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-06 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
모두보기
Beone Medicines Ltd Adr 주식(ONC)의 최신 뉴스
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com
Beigene’s president Wu Xiaobin sells $13.6 million in shares - Investing.com
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer - Benzinga
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
UBS Lifts BEIGENE (06160.HK) TP to $330, Rating Buy - AASTOCKS.com
BeiGene stock price target raised to $334 at TD Cowen By Investing.com - Investing.com South Africa
BeiGene stock price target raised to $334 at TD Cowen - Investing.com
BeiGene stock target raised to $308 on strong FY results - Investing.com India
BeiGene stock target raised to $308 on strong FY results By Investing.com - Investing.com South Africa
BeiGene beats Q4 expectations, sees strong 2025 revenue growth - Investing.com
BeiGene beats Q4 expectations, sees strong 2025 revenue growth By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 - Investing.com India
Beigene's global head of R&D sells $1.29m in shares - Investing.com
Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 21,267 Shares - MarketBeat
BeiGene stock soars to 52-week high of $258.66 amid robust growth - Investing.com India
BeiGene stock soars to 52-week high of $258.66 amid robust growth By Investing.com - Investing.com South Africa
BeiGene’s president sells $12.5 million in company shares - Investing.com India
BeiGene's president sells $12.5 million in company shares - Investing.com
Beigene's Wang Xiaodong sells $9.4 million in shares - Investing.com India
Beigene's Wang Xiaodong sells $9.4 million in shares By Investing.com - Investing.com South Africa
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
CCBI Adds BEIGENE's TP to $179 for Better Fundamentals This Yr - AASTOCKS.com
BEIGENE (06160.HK) Climbs 6% in Early Session, Expects to Achieve Positive Operating Income This Yr - AASTOCKS.com
Beigene director Wang Xiaodong sells $7.37 million in shares - Investing.com
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com
Beigene directors sell shares worth $194.2 million - Investing.com
Beigene sees $274 million stock sale by Hillhouse Investment By Investing.com - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Beigene's Wang Xiaodong sells shares worth $9.19 million - Investing.com
BeiGene settles patent litigation, extends BRUKINSA exclusivity - Investing.com
Beone Medicines Ltd Adr (ONC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.85%
1.81%
자본화:
|
볼륨(24시간):